Literature DB >> 26771969

Prolonged CRP Increase After Percutaneous Coronary Intervention Is Associated with High Thrombin Concentrations and Low Platelet' Response to Clopidogrel in Patients with Stable Angina.

Magdalena Mostowik1, Aleksander Siniarski2, Renata Gołębiowska-Wiatrak2, Jadwiga Nessler3, Grzegorz Gajos3.   

Abstract

BACKGROUND: Inflammation is involved in all stages of development of atherosclerotic plaques. Currently, percutaneous coronary intervention (PCI) is a widely used method of treatment of coronary artery disease (CAD) when combined with optimal medical therapy (OMT). However, there is still controversy over invasive versus optimal pharmacological treatment in stable CAD (SCAD). Systemic inflammatory response triggered by PCI may limit its effectiveness in patients with SCAD.
OBJECTIVES: We aimed to evaluate plasma CRP and its relation to thrombin generation and platelet reactivity both early after the procedure and in a one-month observation following successful PCI with stent implantation, in patients with SCAD and OMT, including statins.
MATERIAL AND METHODS: We conducted a prospective study, in which CRP, platelet activation, thrombin generation and time course of prothrombin activation were determined at baseline, 3-5 days and 30 days after successful PCI with stent implantation, in 50 consecutive patients with SCAD, on chronic statin therapy.
RESULTS: Early after PCI CRP increased by 176% as compared with baseline (p < 0.001) and one-month after angioplasty CRP was still 54% higher than before the procedure (p = 0.002). In multivariate model prolonged increase in CRP 1 month after PCI was independently associated with P2Y12-reactivity index (PRI) (p = 0.04) and maximum concentration of thrombin (p = 0.003), both measured 30 days after the procedure.
CONCLUSIONS: Post-procedural CRP increase, which persists at least one month in patients with SCAD, after elective PCI with stent implantation, is one of the main finding of our study. We demonstrated the relationship between prolonged post-PCI inflammatory reaction, reflected by elevated CRP, and increased thrombin generation and low platelets' response to clopidogrel, which may account for limited benefits of PCI in stable coronary patients. It may be advisable to assay post-procedural CRP in each patient with SCAD, who underwent PCI to predict those, with potentially low response to clopidogrel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26771969     DOI: 10.17219/acem/46935

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  4 in total

Review 1.  Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease.

Authors:  Davide Capodanno; Deepak L Bhatt; John W Eikelboom; Keith A A Fox; Tobias Geisler; C Michael Gibson; Jose Ramon Gonzalez-Juanatey; Stefan James; Renato D Lopes; Roxana Mehran; Gilles Montalescot; Manesh Patel; P Gabriel Steg; Robert F Storey; Pascal Vranckx; Jeffrey I Weitz; Robert Welsh; Uwe Zeymer; Dominick J Angiolillo
Journal:  Nat Rev Cardiol       Date:  2020-01-17       Impact factor: 32.419

2.  Clopidogrel in Critically Ill Patients.

Authors:  Christian Schoergenhofer; Eva-Luise Hobl; Peter Schellongowski; Gottfried Heinz; Walter S Speidl; Jolanta M Siller-Matula; Monika Schmid; Raute Sunder-Plaßmann; Thomas Stimpfl; Matthias Hackl; Bernd Jilma
Journal:  Clin Pharmacol Ther       Date:  2017-11-03       Impact factor: 6.875

3.  The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance.

Authors:  Shaoyi Lin; Xiaofeng Xu; Haochang Hu; Ji Cheng; Ruoyu Chen; Yingchu Hu; Xiaomin Chen
Journal:  Pharmacol Res Perspect       Date:  2021-04

4.  Assessment of Platelet Reactivity and Inflammatory Markers in Coronary Artery Bypass Graft Patients Treated with Acetylsalicylic Acid with Flavonoid Supplementation.

Authors:  Aldona Siennicka; Magdalena Kłysz; Monika Adamska; Kornel Chełstowski; Andrzej Biskupski; Maria Jastrzębska
Journal:  Molecules       Date:  2021-12-10       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.